Completed PHASE3 INTERVENTIONAL 2-arm NCT00006083

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Cervical Cancer Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Precancerous/Nonmalignant Condition Unspecified Adult Solid Tumor, Protocol Specific Veno-occlusive Disease

Interventions Fragmin placebo

Updated 7 times since 2017 Last updated: Jul 30, 2020 Started: Apr 30, 2000 Primary completion: Nov 30, 2000 Completion: Nov 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00006083, this PHASE3 trial focuses on Cervical Cancer and Chronic Myeloproliferative Disorders and remains completed. Sponsored by Jonsson Comprehensive Cancer Center, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2020 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jonsson Comprehensive Cancer Center
Upjohn

Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States